产品详情
文献和实验
相关推荐
LentiVector® platform
Pipeline
Bioprocessing
牛津生物医学是一家领先的、完全整合的细胞和基因治疗集团
我们已经建立了行业领先的慢病毒载体交付系统，即LentiVector®平台，我们利用该平台在内部和与合作伙伴共同开发体内和体外产品。我们还在肿瘤学、眼科学、中枢神经系统疾病和肝脏疾病领域创建了一个宝贵的细胞和基因治疗候选产品专利组合。
牛津生物医学已与诺华、朱诺治疗/百时美施贵宝、SIO基因治疗、乌节治疗、桑顿、Beam治疗、勃林格·英格海姆、英国囊性纤维化基因治疗联盟和帝国创新等多家公司建立了合作关系。
此外，我们还2019冠状病毒疾病疫苗供应公司和阿斯利康公司的三年供应和发展协议。
牛津生物医学总部位于英国牛津郡的多个地点，员工超过740人。
Oxford Biomedica is a leading, fully integrated, cell and gene therapy group
We have built a sector leading lentiviral vector delivery system, LentiVector® platform, which we leverage to develop in vivo and ex vivo products both in-house and with partners. We have also created a valuable proprietary portfolio of cell and gene therapy product candidates in the areas of oncology, ophthalmology, CNS disorders and liver diseases.
Oxford Biomedica has entered into a number of partnerships, including with Novartis, Juno Therapeutics/Bristol Myers Squibb, SIO Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial nnovations.
Additionally, we have a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine.
Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people.
Pipeline
Bioprocessing
牛津生物医学是一家领先的、完全整合的细胞和基因治疗集团
我们已经建立了行业领先的慢病毒载体交付系统，即LentiVector®平台，我们利用该平台在内部和与合作伙伴共同开发体内和体外产品。我们还在肿瘤学、眼科学、中枢神经系统疾病和肝脏疾病领域创建了一个宝贵的细胞和基因治疗候选产品专利组合。
牛津生物医学已与诺华、朱诺治疗/百时美施贵宝、SIO基因治疗、乌节治疗、桑顿、Beam治疗、勃林格·英格海姆、英国囊性纤维化基因治疗联盟和帝国创新等多家公司建立了合作关系。
此外，我们还2019冠状病毒疾病疫苗供应公司和阿斯利康公司的三年供应和发展协议。
牛津生物医学总部位于英国牛津郡的多个地点，员工超过740人。
Oxford Biomedica is a leading, fully integrated, cell and gene therapy group
We have built a sector leading lentiviral vector delivery system, LentiVector® platform, which we leverage to develop in vivo and ex vivo products both in-house and with partners. We have also created a valuable proprietary portfolio of cell and gene therapy product candidates in the areas of oncology, ophthalmology, CNS disorders and liver diseases.
Oxford Biomedica has entered into a number of partnerships, including with Novartis, Juno Therapeutics/Bristol Myers Squibb, SIO Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial nnovations.
Additionally, we have a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine.
Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people.
北京美科美生物技术开发有限公司
代理商实名认证
钻石会员
入驻年限：11年
